317 related articles for article (PubMed ID: 28255870)
1. Efficacy and Safety of Lomitapide in Hypercholesterolemia.
Liu X; Men P; Wang Y; Zhai S; Zhao Z; Liu G
Am J Cardiovasc Drugs; 2017 Aug; 17(4):299-309. PubMed ID: 28255870
[TBL] [Abstract][Full Text] [Related]
2. Safety and Efficacy of Lomitapide in Japanese Patients with Homozygous Familial Hypercholesterolemia (HoFH): Results from the AEGR-733-301 Long-Term Extension Study.
Nohara A; Otsubo Y; Yanagi K; Yoshida M; Ikewaki K; Harada-Shiba M; Jurecka A
J Atheroscler Thromb; 2019 Apr; 26(4):368-377. PubMed ID: 30259883
[TBL] [Abstract][Full Text] [Related]
3. Review of the long-term safety of lomitapide: a microsomal triglycerides transfer protein inhibitor for treating homozygous familial hypercholesterolemia.
Khoury E; Brisson D; Roy N; Tremblay G; Gaudet D
Expert Opin Drug Saf; 2019 May; 18(5):403-414. PubMed ID: 30945578
[TBL] [Abstract][Full Text] [Related]
4. Lomitapide in homozygous familial hypercholesterolemia: cardiology perspective from a single-center experience.
Sperlongano S; Gragnano F; Natale F; D'Erasmo L; Concilio C; Cesaro A; Golia E; Crisci M; Sperlongano R; Fimiani F; Russo M; Arca M; Limongelli G; Calabrò P
J Cardiovasc Med (Hagerstown); 2018 Mar; 19(3):83-90. PubMed ID: 29389816
[TBL] [Abstract][Full Text] [Related]
5. Lomitapide for the treatment of hypercholesterolemia.
Berberich AJ; Hegele RA
Expert Opin Pharmacother; 2017 Aug; 18(12):1261-1268. PubMed ID: 28598687
[TBL] [Abstract][Full Text] [Related]
6. Lomitapide: A novel agent for the treatment of homozygous familial hypercholesterolemia.
Davis KA; Miyares MA
Am J Health Syst Pharm; 2014 Jun; 71(12):1001-8. PubMed ID: 24865757
[TBL] [Abstract][Full Text] [Related]
7. Lomitapide for the management of homozygous familial hypercholesterolemia.
deGoma EM
Rev Cardiovasc Med; 2014; 15(2):109-18. PubMed ID: 25051128
[TBL] [Abstract][Full Text] [Related]
8. Microsomal triglyceride transfer protein inhibitor (lomitapide) efficacy in the treatment of patients with homozygous familial hypercholesterolaemia.
Kolovou G; Diakoumakou O; Kolovou V; Fountas E; Stratakis S; Zacharis E; Liberopoulos EN; Matsouka F; Tsoutsinos A; Mastorakou I; Katsikas T; Mavrogeni S; Hatzigeorgiou G
Eur J Prev Cardiol; 2020 Jan; 27(2):157-165. PubMed ID: 31403880
[TBL] [Abstract][Full Text] [Related]
9. Lomitapide and mipomersen: novel lipid-lowering agents for the management of familial hypercholesterolemia.
Dixon DL; Sisson EM; Butler M; Higbea A; Muoio B; Turner B
J Cardiovasc Nurs; 2014; 29(5):E7-E12. PubMed ID: 24231894
[TBL] [Abstract][Full Text] [Related]
10. Lomitapide-a Microsomal Triglyceride Transfer Protein Inhibitor for Homozygous Familial Hypercholesterolemia.
Stefanutti C
Curr Atheroscler Rep; 2020 Jun; 22(8):38. PubMed ID: 32557261
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic Options for Homozygous Familial Hypercholesterolemia: The Role of Lomitapide.
Giammanco A; Cefalù AB; Noto D; Averna MR
Curr Med Chem; 2020; 27(23):3773-3783. PubMed ID: 30663562
[TBL] [Abstract][Full Text] [Related]
12. Lomitapide, a microsomal triglyceride transfer protein inhibitor for the treatment of hypercholesterolemia.
Rizzo M
IDrugs; 2010 Feb; 13(2):103-11. PubMed ID: 20127562
[TBL] [Abstract][Full Text] [Related]
13. The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia - a post-hoc analysis of a Phase 3, single-arm, open-label trial.
Stefanutti C; Blom DJ; Averna MR; Meagher EA; Theron Hd; Marais AD; Hegele RA; Sirtori CR; Shah PK; Gaudet D; Vigna GB; Sachais BS; Di Giacomo S; du Plessis AM; Bloedon LT; Balser J; Rader DJ; Cuchel M;
Atherosclerosis; 2015 Jun; 240(2):408-14. PubMed ID: 25897792
[TBL] [Abstract][Full Text] [Related]
14. Treating homozygous familial hypercholesterolemia in a real-world setting: Experiences with lomitapide.
Roeters van Lennep J; Averna M; Alonso R
J Clin Lipidol; 2015; 9(4):607-17. PubMed ID: 26228681
[TBL] [Abstract][Full Text] [Related]
15. Microsomal transfer protein inhibition in humans.
Cuchel M; Rader DJ
Curr Opin Lipidol; 2013 Jun; 24(3):246-50. PubMed ID: 23594709
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of Lomitapide in the Treatment of Familial Homozygous Hypercholesterolemia: Results of a Real-World Clinical Experience in Italy.
D'Erasmo L; Cefalù AB; Noto D; Giammanco A; Averna M; Pintus P; Medde P; Vigna GB; Sirtori C; Calabresi L; Pavanello C; Bucci M; Sabbà C; Suppressa P; Natale F; Calabrò P; Sampietro T; Bigazzi F; Sbrana F; Bonomo K; Sileo F; Arca M
Adv Ther; 2017 May; 34(5):1200-1210. PubMed ID: 28432645
[TBL] [Abstract][Full Text] [Related]
17. Long-term efficacy of lipoprotein apheresis and lomitapide in the treatment of homozygous familial hypercholesterolemia (HoFH): a cross-national retrospective survey.
D'Erasmo L; Gallo A; Cefalù AB; Di Costanzo A; Saheb S; Giammanco A; Averna M; Buonaiuto A; Iannuzzo G; Fortunato G; Puja A; Montalcini T; Pavanello C; Calabresi L; Vigna GB; Bucci M; Bonomo K; Nota F; Sampietro T; Sbrana F; Suppressa P; Sabbà C; Fimiani F; Cesaro A; Calabrò P; Palmisano S; D'Addato S; Pisciotta L; Bertolini S; Bittar R; Kalmykova O; Béliard S; Carrié A; Arca M; Bruckert E
Orphanet J Rare Dis; 2021 Sep; 16(1):381. PubMed ID: 34496902
[TBL] [Abstract][Full Text] [Related]
18. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
Sahebkar A; Watts GF
Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
[TBL] [Abstract][Full Text] [Related]
19. Homozygous Familial Hypercholesterolemia (HoFH) in Saudi Arabia and Two Cases of Lomitapide Use in a Real-World Setting.
Mahzari M; Zarif H
Adv Ther; 2021 May; 38(5):2159-2169. PubMed ID: 33829367
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of hepatic microsomal triglyceride transfer protein - a novel therapeutic option for treatment of homozygous familial hypercholesterolemia.
Vuorio A; Tikkanen MJ; Kovanen PT
Vasc Health Risk Manag; 2014; 10():263-70. PubMed ID: 24851052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
